Request Demo

Last update 23 Dec 2025

Valsartan

Last update 23 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryValsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs), which exhibit the ability to selectively obstruct the angiotensin receptor type 1 (AR1R), hence deterring the effects of angiotensin II on the blood vessels, and consequently regulating the blood pressure. It is noteworthy that Valsartan is primarily intended to treat hypertension, heart failure, and myocardial infarction, with its debut approval by the FDA dating back to December 1996, all thanks to the efforts of Novartis in developing it. Valsartan has become widely recognized and hailed as a vital drug in the management of cardiovascular diseases, which serves as a testament to its efficacy and utility.

Drug Type

Small molecule drug

Synonyms

(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine, Diovane, Kalpress

+ [25]

Target

AT1R

Action

antagonists

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Myocardial InfarctionHeart FailureHypertension

Inactive Indication

Acute Coronary SyndromeAcute Ischemic StrokeChronic heart failure+ [5]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Pharmaceuticals Australia Pty Ltd.

Novartis Pharmaceuticals Corp.

Novartis Pharma KK

Inactive Organization

Novartis AG

Novartis Pharmaceuticals Canada, Inc.

Carmel Biosciences, Inc.

License Organization

Medicure, Inc.

Carmel Biosciences, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (23 Dec 1996),

Heart FailureHypertension

Regulation-

Structure/Sequence

Molecular FormulaC24H29N5O3

InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N

CAS Registry137862-53-4

420

Clinical Trials associated with Valsartan

NCT07139405

/ Not yet recruitingPhase 2

A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE II TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND SUPERIORITY OF TRIGLYTZA® OVER METFORMIN IN PATIENTS WITH INADEQUATE GLYCEMIC CONTROL OVER 24 WEEKS OF TREATMENT

Type 2 diabetes (T2DM) is still very difficult to treat because current medicines mostly help with symptoms but don't stop the damage happening inside the pancreas. Many people who start on common treatments like Metformin, and even newer drugs like Ozempic, eventually stop responding to them. This is because these drugs don't address the real problem: the gradual loss of the pancreas' ability to make insulin and the body's increasing resistance to it.
Myopharm is developing a new treatment called TriGlytza®, which combines existing medicines (Celecoxib and Valsartan) with Metformin. This new approach is designed to target the inflammation and biological pathways that cause ongoing damage in Type 2 diabetes, aiming to protect the pancreas and reduce insulin resistance. Early animal studies and past clinical trials with the individual drugs show promising results.
The number of people with Type 2 diabetes is expected to double by 2045, and the disease brings huge health and financial costs. It also raises the risk of heart disease, stroke, kidney damage, nerve problems, vision loss, certain cancers, and even conditions like Alzheimer's. Because of this, a treatment that addresses the root causes rather than just symptoms could make a major difference.
TriGlytza® aims to provide a safe, affordable, and more effective long-term treatment than current options, helping people manage their diabetes better and avoid related health problems.

Start Date01 Feb 2026

Sponsor / Collaborator

Myopharm Ltd.

ChiCTR2500114779

/ Not yet recruitingNot ApplicableIIT

A randomized, controlled, open-label cohort clinical study to evaluate the incidence of radiation pneumonitis six months after treatment with valsartan combined with thoracic radiotherapy and immune checkpoint inhibitors versus thoracic radiotherapy and immune checkpoint inhibitors alone

Start Date30 Dec 2025

Sponsor / Collaborator

Jinan Central Hospital

CTR20254639

/ Active, not recruitingNot Applicable

单中心、随机、开放、四周期、四交叉试验评价中国成年健康受试者单次空腹口服NHKC-1、苯磺酸氨氯地平片（络活喜）、缬沙坦片（DIOVAN）、缬沙坦胶囊（代文）的药代动力学比较研究

[Translation] A single-center, randomized, open-label, four-period, four-crossover trial comparing the pharmacokinetics of NHKC-1, amlodipine besylate tablets (Norvasc), valsartan tablets (DIOVAN), and valsartan capsules (Diovan) in healthy adult Chinese subjects after a single fasting oral administration.

主要研究目的：评价中国成年健康受试者单次空腹口服NHKC-1、苯磺酸氨氯地平片（络活喜）、缬沙坦片（DIOVAN）、缬沙坦胶囊（代文）的药代动力学特征、相对生物利用度和相互作用。次要研究目的：评价中国成年健康受试者空腹口服NHKC-1、苯磺酸氨氯地平片（络活喜）、缬沙坦片（DIOVAN）、缬沙坦胶囊（代文）的安全性。

[Translation]

Primary Study Objective: To evaluate the pharmacokinetic characteristics, relative bioavailability, and interactions of a single fasting oral dose of NHKC-1, amlodipine besylate tablets (Norvasc), valsartan tablets (DIOVAN), and valsartan capsules (Diovan) in healthy adult Chinese subjects. Secondary Study Objective: To evaluate the safety of fasting oral administration of NHKC-1, amlodipine besylate tablets (Norvasc), valsartan tablets (DIOVAN), and valsartan capsules (Diovan) in healthy adult Chinese subjects.

Start Date26 Nov 2025

Sponsor / Collaborator

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

[+1]

100 Clinical Results associated with Valsartan

100 Translational Medicine associated with Valsartan

100 Patents (Medical) associated with Valsartan

7,634

Literatures (Medical) associated with Valsartan

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Wenyang Xiaozheng decoction modulates macrophage polarization via JAK2/STAT3 signaling pathway to reduce renal fibrosis

Article

Author: Lin, Xiaomeng ; Duan, Jiamin ; Zhong, Guanghui ; Peng, Xin ; Cai, Xudong ; He, Liqun ; Yu, Kena ; Lu, Hanyu

ETHNOPHARMACOLOGICAL RELEVANCE:

Wenyang Xiaozheng Decoction (WYXZ), a traditional Chinese medicine formula based on the principles of "warming Yang and resolving blood stasis," has been clinically shown to improve renal function in patients with chronic kidney disease (CKD). However, the precise mechanisms underlying its therapeutic effects remain to be elucidated.

AIM OF THE STUDY:

To investigate whether WYXZ alleviates renal fibrosis by modulating macrophage polarization via JAK2/STAT3 signaling.

MATERIALS AND METHODS:

Renal fibrosis was induced in C57BL/6J mice by 5/6 nephrectomy, followed by treatment with WYXZ (4.94 or 9.88 g/kg) or valsartan for 8 weeks. Kidney function (serum creatinine/blood urea nitrogen), histopathology (HE/Masson staining), and macrophage polarization (CD86⁺/CD206⁺ flow cytometry) were assessed. In vitro, RAW264.7 macrophages were polarized to M1/M2 phenotypes and treated with WYXZ-medicated serum (2.5-7.5 %) ± JAK2 agonist Butyzamide or STAT3 shRNA. Inflammatory responses (IL-6/IL-10 secretion by ELISA), polarization status (flow cytometry), and JAK2/STAT3 pathway activation (phosphorylated-JAK2/STAT3 by Western blot) were analyzed. Fibrosis markers (α-smooth muscle actin, α-SMA/collagen I, Col-I) were evaluated in RAW264.7/HK-2 co-cultures.

RESULTS:

WYXZ significantly attenuated renal fibrosis and improved kidney function in 5/6 nephrectomized mice, concurrently suppressing M1 macrophage polarization while enhancing M2 polarization. In vitro, WYXZ-medicated serum reduced inflammatory cytokine secretion and inhibited JAK2/STAT3 pathway activation in LPS-stimulated macrophages. These effects were reversed by JAK2 agonism with Butyzamide and abolished through STAT3 knockdown. Critically, in macrophage-renal tubular cell co-cultures, WYXZ diminished fibrotic marker expression via suppression of macrophage JAK2/STAT3 signaling.

CONCLUSIONS:

WYXZ attenuates renal fibrosis by reprogramming macrophage polarization through JAK2/STAT3 inhibition, validating its traditional use for CKD.

31 Dec 2025·RENAL FAILURE

Dose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study

Article

Author: Nakano, Yusuke ; Oonishi, Masafumi ; Hamada, Yukihiro ; Kato, Takahiro ; Yasukawa, Noriko

To evaluate the dose-dependent renoprotective effects of sacubitril/valsartan in heart failure patients. This retrospective observational study included patients with heart failure (Stage B or higher, B-type natriuretic peptide (BNP) >100 pg/mL or N-terminal proBNP >300 pg/mL) who initiated sacubitril/valsartan (SV) treatment. Patients were classified by final SV daily dose (50, 100, 200, or 400 mg) at 18 months. Factors associated with eGFR changes were identified using multiple regression analysis. A total of 157 patients (mean age 74.8-77.9 years, 64.3% male) were stratified by daily SV dosage groups (50 mg, n = 20; 100 mg, n = 46; 200 mg, n = 62; 400 mg, n = 29). Baseline characteristics were similar across groups for eGFR, heart failure stage, diabetes history, myocardial infarction, atrial fibrillation, proteinuria, and use of most heart failure medications. However, hypertension prevalence and systolic blood pressure differed significantly between groups (p < 0.05). One-way ANOVA revealed significant dose-dependent differences in eGFR changes among SV dosage groups (p < 0.05). In the final multiple linear regression model, SV dosage (p < 0.05) was a significant factor associated with eGFR changes, with proteinuria showing a trend toward significance. Sex and BNP levels ≥400 pg/dL were not significant. Sensitivity analysis converting SV dosage to a categorical variable confirmed these findings. Stratification by proteinuria status demonstrated dose-dependent relationships in both proteinuria-positive and proteinuria-negative subgroups, with more pronounced dose dependency in the proteinuria-positive group (p < 0.001). SV exhibits dose-dependent renoprotective effects in heart failure patients. Optimizing SV dosage may be beneficial for heart failure patients with concurrent kidney dysfunction, especially those with proteinuria.

01 Dec 2025·Journal of Gastrointestinal Cancer

Retraction Note: Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil

Article

Author: Naghibzadeh, Niloufar ; Avan, Amir ; Khazaei, Majid ; Mostafapour, Asma ; Hassanian, Seyed Mahdi ; Hashemzehi, Milad ; Asgharzadeh, Fereshteh

News (Medical) associated with Valsartan

10 Dec 2025

·www.globenewswire.com

New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD

New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant Hypertension”.1 The analysis examined the efficacy and safety of aprocitentan (TRYVIO™/JERAYGO™) in patients with chronic kidney disease (CKD) and confirmed resistant hypertension – a population with very limited treatment options and high cardiovascular and renal risk. Aprocitentan, the first approved antihypertensive targeting the endothelin pathway, was well tolerated. It significantly reduced both office and nighttime ambulatory blood pressure (BP), as well as markedly lowered albuminuria – a key marker of kidney damage – without increasing the risk of hyperkalemia. Patrick Rossignol, MD, PhD, nephrologist, Head of the Medical Specialties and nephrology departments at the Princess Grace Hospital, Monaco, commented:“Hypertension is both a cause and consequence of chronic kidney disease (CKD) and managing it in these patients is particularly challenging. Blood pressure is often difficult to control, and many antihypertensive agents carry risks of worsening renal function or causing hypo or hyperkalemia, which are all associated with dismal outcomes. The data presented in this manuscript are truly transformative for our patients: aprocitentan not only markedly lowered blood pressure but also reduced proteinuria by up to 60% on top of standardized background triple therapy including valsartan and a thiazide-like diuretic – without inducing dyskalemia or worsening renal function. Its favorable safety profile and exceptionally low discontinuation rate after nearly one year of treatment position aprocitentan as a fundamental advancement for patients with CKD and treatment resistant hypertension.” Martine Clozel, MD, Chief Scientific Officer and Head of Research at Idorsia, commented: “The PRECISION study included patients with confirmed resistant hypertension without excluding patients with stage 3 or 4 chronic kidney disease (CKD), as these patients are particularly underserved. The endothelin pathway plays a clear role in both kidney dysfunction and hypertension, yet until aprocitentan, no antihypertensive therapy targeted this pathway – explaining why many patients were not responding to treatment. TRYVIO/JERAYGO blocks the two endothelin receptor subtypes fundamental in its actions. In patients who had often tried more than four antihypertensive drugs, aprocitentan delivered significant blood pressure reductions alongside a major antiproteinuric effect, suggesting meaningful renal protection.” There are 1.4 billion people worldwide living with hypertension.2 Hypertension remains a leading global health challenge and the number one modifiable risk factor for early morbidity and mortality. Despite advances in treatment, many patients still struggle with uncontrolled blood pressure, leaving them at significantly higher risk of heart attack, stroke, kidney failure, and premature death.3 In the US, approximately 50% of patients living with hypertension on multiple treatments do not have their blood pressure under control.4 In patients with CKD, hypertension significantly contributes to preventable morbidity and mortality and is a leading cause of cardiovascular disease.5-7 In 2019, there were more than 650 million people with CKD worldwide and 1.2 million deaths due to CKD.8 Especially nocturnal hypertension has been associated with increased cardiovascular morbidity.9-11 Therefore, appropriate and effective management of hypertension is a key strategy of managing patients with CKD.12,13 Endothelin-1 (ET-1) is a potent vasoconstrictor that also induces neurohormonal activation, vascular hypertrophy and remodeling, cardiac hypertrophy and fibrosis, and endothelial dysfunction. In hypertension, both ETA and ETB receptors mediate harmful effects of ET-1.14 As a vasoconstrictor, co-mitogenic agent, linking pulse pressure and vascular remodeling, and mediator of aldosterone and catecholamine release, endothelin is a key player in hypertension and end-organ damage.15,16 Upregulation of endothelin-1 is considered an important contributor to the pathophysiology of CKD progression, including increased blood pressure, glomerular membrane permeability, mesangial cell proliferation, podocyte dysfunction, interstitial inflammation and fibrosis.17,18 About the analysis1The Phase 3 PRECISION study evaluated aprocitentan in 730 patients with confirmed resistant hypertension. This post-hoc analysis focused on the 147 participants with CKD categorized as high or very high risk according to KDIGO criteria.19 At Week 4, aprocitentan 12.5 mg and 25 mg reduced office systolic BP by –13.5 mm Hg and –16.6 mm Hg, respectively, versus –4.4 mm Hg with placebo – with reductions sustained with aprocitentan 25 mg through Week 36 (-16.4 mm Hg)Nighttime ambulatory systolic BP – a strong predictor of cardiovascular and renal outcomes and often poorly controlled in CKD – was reduced by –9.6 mm Hg and –13.8 mm Hg, respectively, versus –2.5 mm Hg with placebo.UACR – a marker of kidney damage and progression – was reduced by –47.1% and –59.6%, respectively, versus –2.4% with placebo – with reductions associated with improved long-term prognosis sustained through Week 36 (–61.6%).Aprocitentan was generally well tolerated. The most common adverse event was mild-to-moderate peripheral edema, typically seen early on and managed with diuretic adjustment. No significant changes in potassium or estimated glomerular filtration rate (eGFR) were observed. About aprocitentanAprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO® in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide). TRYVIO is now included in the American College of Cardiology’s (ACC) and the American Heart Association’s (AHA) new comprehensive clinical practice guidelines for the management of high blood pressure. Aprocitentan is approved as JERAYGO® for the treatment of resistant hypertension in combination with other antihypertensives in the European Union, the UK, and Switzerland, and a marketing authorization application is under review in Canada. About PRECISION20,21 (NCT03541174)PRECISION was a multicenter, blinded, randomized, parallel-group, Phase 3 study, which was performed in hospitals or research centers in Europe, North America, Asia, and Australia. Patients were eligible for randomization if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardized background therapy consisting of three antihypertensive drugs, including a diuretic. The study consisted of three sequential parts: Part 1 was the 4-week double-blind, randomized, and placebo-controlled part, in which 730 patients were randomized to aprocitentan 12.5 mg (n=243), aprocitentan 25 mg (n=243), or placebo (n=244) in a 1:1:1 ratio; Part 2 was a 32-week single (patient)-blind part, in which all patients received aprocitentan 25 mg (n=704); and Part 3 was a 12-week double-blind, randomized, and placebo-controlled withdrawal part, in which patients were re-randomized to aprocitentan 25 mg (n=307) or placebo (n=307) in a 1:1 ratio. The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes. At baseline, 69.2% of patients were obese or severely obese, 54.1% had diabetes, 22.2% had stage 3-4 chronic kidney disease and 19.6% had congestive heart failure. 63% of randomized patients were receiving at least 4 anti-hypertensive therapies at screening. Key PRECISION findings21 The least square mean change in office SBP at 4 weeks was –15.3 mmHg for aprocitentan 12.5 mg, –15.2 mmHg for 25 mg, and –11.5 mmHg for placebo, for a difference versus placebo of –3.8 mmHg (p=0.0042) and –3.7 mmHg (p=0.0046), respectively. Office diastolic blood pressure (DBP) also decreased with both aprocitentan doses compared to placebo (–3.9 mmHg for the 12.5 mg dose and –4.5 mmHg for the 25 mg dose). Office SBP and DBP were maintained during Part 2 in patients previously receiving aprocitentan and decreased within the first 2 weeks of Part 2 before stabilizing in those previously receiving placebo. In Part 3, office SBP after 4 weeks of withdrawal (the key secondary endpoint) increased significantly with placebo compared to aprocitentan (5.8 mmHg; p<0.0001). Office DBP also increased with placebo compared to aprocitentan (5.2 mmHg; p<0.001). The difference between the two groups remained up to week 48. The results from ambulatory BP monitoring, a strong predictor of cardiovascular mortality,1,2 confirmed those derived from office measurements. At the end of Part 1, aprocitentan, after placebo correction, decreased both the 24-hour ambulatory SBP (–4.2 mmHg for the 12.5 mg dose and –5.9 mmHg for the 25 mg dose) and DBP (–4.3 mmHg for the 12.5 mg dose and –5.8 mmHg for the 25 mg dose). The placebo-corrected SBP lowering effect was –5.1 mmHg and –7.4 mmHg during the nighttime and –3.8 mmHg and –5.3 mmHg during the daytime, for the 12.5 mg and 25 mg doses, respectively. In Part 3, after 4 weeks of withdrawal (week 40), both the 24-hour ambulatory SBP and DBP increased with placebo compared with aprocitentan (6·5 mm Hg and 6·8 mm Hg respectively). Treatment-emergent adverse events (TEAEs) during the 4-week double-blind study period (Part 1) were reported in 27.6% and 36.7% of the patients treated with 12.5 and 25 mg aprocitentan, respectively, versus 19.4% in the placebo group. The most frequent adverse event was fluid retention which was reported more frequently with aprocitentan than with placebo in a dose-dependent fashion (9.1%, 18.4%, and 2.1% for patients receiving aprocitentan 12.5 mg, 25 mg and placebo, during Part 1, respectively; 18.2% for patients receiving aprocitentan 25 mg during Part 2; and 2.6% and 1.3% for patients on aprocitentan 25 mg and placebo, during Part 3, respectively). Fluid retention was generally mild-to-moderate, was primarily peripheral edema and was manageable by current clinical practice including use of diuretics. Discontinuation due to edema/fluid retention was reported for seven patients. Notes to the editor About Dr Patrick Rossignol, MD, PhDPatrick Rossignol is a nephrologist and vascular medicine specialist, European Society of Hypertension-certified hypertension specialist and formerly a Professor of Therapeutics at the University of Lorraine, France. Since 2022, he is heading the Department of Medicine specialties and nephrology-hemodialysis at the Princess Grace Hospital, in Monaco. He is also the medical director of the private hemodialysis Centre, in Monaco. He is chairing Monaco Clinical Research Infrastructure Network (M-CRIN) since its creation in 2025.He is the Coordinator of the FCRIN INI-CRCT (Cardiovascular and Renal Clinical trialists network of excellence www.inicrct.fr,) since its creation 2014, FCRIN being the “French Clinical research Infrastructure network”. From 2018 to 2022, he used to be the Director of the Nancy University Hospital INSERM Clinical Investigation Centre, after serving as its Deputy Director for ten years. He is now an associate researcher. He is also the Kidney Disease Clinical Trialists (KDCT) workshop course director. Professor Rossignol has been involved in numerous clinical trials in the settings of heart failure, hypertension and chronic kidney disease as well as in translational basic research studies on the cardiorenal syndrome. He has published more than 700 peer-reviewed publications and is co-inventor of 9 biomarker international patents in the cardiorenal syndrome setting. Prof Rossignol used to serve as a consultant to Idorsia while he was chairing the PRECISION trial critical event committee. References Rossignol P, et al. Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension. Hypertension. Online ahead of print, December 2025, doi.org/10.1161/HYPERTENSIONAHA.125.25563World Health Organization. Global report on hypertension 2025: high stakes: turning evidence into action. 2025.Murray, Christopher J L. Findings from the Global Burden of Disease Study 2021. The Lancet. 2024; 403 (10440): 2259 - 2262Carey RM, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431Rossignol P, Massy ZA, Azizi M, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386(10003):1588-1598.Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. Am J Hypertens. 2024;37(6):438-446.Kidney Disease: Improving Global Outcomes Blood Pressure Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.Liu Y, He Q, Li Q, et al. Global incidence and death estimates of chronic kidney disease due to hypertension from 1990 to 2019, an ecological analysis of the global burden of diseases 2019 study. BMC Nephrol. 2023;24(1):352.Huart J, Persu A, Lengele JP, Krzesinski JM, Jouret F, Stergiou GS. Pathophysiology of the Nondipping Blood Pressure Pattern. Hypertension. 2023;80(4):719-729.Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156-161.Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011;57(1):3-10.Kreutz R, Brunstrom M, Burnier M, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15.Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.Kedzierski RM, et al. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001; 41:851-76.Iglarz M, et al. At the heart of tissue: endothelin system and end-organ damage. Clin Sci 2010; 119:453-63.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398:957-80.Smeijer JD, Kohan DE, Dhaun N, Noronha IL, Liew A, Heerspink HJL. Endothelin receptor antagonists in chronic kidney disease. Nat Rev Nephrol. 2024.Dhaun N, Webb DJ, Kluth DC. Endothelin-1 and the kidney--beyond BP. Br J Pharmacol. 2012;167(4):720-731.Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.Danaietash P et al. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertension 2022 Jul;24(7):804-813.Schlaich MP, et al. A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension. The Lancet, 2022; Dec 3;400(10367):1927-1937. About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

Clinical ResultPhase 3Drug ApprovalAHA

19 Sep 2025

·www.idorsia.com

Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension

Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive therapy – the first systemic hypertension treatment to target a new pathway in over 30 years. Allschwil, Switzerland – September 19, 2025Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.1 Hypertension remains a leading global health challenge and the number one modifiable risk factor for early morbidity and mortality. Despite advances in treatment, many patients still struggle with uncontrolled blood pressure, leaving them at significantly higher risk of heart attack, stroke, kidney failure, and premature death. Approximately 10% of hypertensive patients have resistant hypertension3,4 – defined by uncontrolled blood pressure despite receiving at least three antihypertensive medications from different classes, at optimal doses – underscoring the urgent need for more effective therapies. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented:“JERAYGO is the first and only hypertension treatment to target the endothelin pathway, a fundamental yet previously unaddressed driver of disease onset, progression, and complications. This breakthrough reflects nearly 30 years of research at our Swiss laboratories and represents Idorsia’s second product approval in our home country. JERAYGO has demonstrated rapid, durable, and clinically significant double-digit blood pressure reduction across a broad spectrum of challenging patient populations, including those with obesity, chronic kidney disease, or type 2 diabetes. I am incredibly proud of our team for achieving this milestone.” Idorsia is engaged in discussions with potential partners to make JERAYGO available to patients across Switzerland and Europe. For more information on the marketing authorization of JERAYGO in Switzerland, please refer to the Patient Information and Information for Healthcare Professionals. Notes to the editor About the Phase 3 PRECISION study1,5The efficacy of aprocitentan was evaluated in one randomized, double-blind (DB), placebo-controlled Phase 3 multicenter study. Patients with uncontrolled blood pressure (systolic blood pressure [SBP] ≥140 mmHg) despite the use of at least three antihypertensive medicinal products and following exclusion of pseudo-resistant hypertension (e.g., white coat effect, inappropriate blood pressure measurement, secondary causes of hypertension) were considered to have resistant hypertension. The patients were switched to standardized background antihypertensive therapy consisting of an angiotensin receptor blocker (valsartan 160 mg), a calcium channel blocker (amlodipine 5 or 10 mg), and a diuretic (hydrochlorothiazide 25 mg) throughout the study. Patients with concomitant use of beta-blockers continued this treatment throughout the study, in addition to the standardized background antihypertensive therapy and study treatment. A total of 730 patients received either aprocitentan 12.5 mg, aprocitentan 25 mg, or placebo once daily during the initial 4-week DB treatment (part 1). Thereafter, patients received aprocitentan 25 mg once daily during the 32-week single-blind treatment (part 2). At the end of the 32 weeks, patients were re-randomized to receive either aprocitentan 25 mg or placebo, once daily, during the 12-week double-blind withdrawal (DB-WD) treatment (part 3). The primary efficacy endpoint was the change in sitting SBP (SiSBP) from baseline to Week 4 during DB treatment (part 1), measured at trough by unattended automated office blood pressure (uAOBP). The key secondary endpoint was the change in SiSBP measured at trough by uAOBP from DB-WD baseline (Week 36) to Week 40 (part 3). Patients had a mean age of 61.7 years (range 24 to 84 years; 34.1% were ≥ 65 and < 75 years; 9.9% were ≥ 75 years) and 59.5% were male. Patients were White (82.9%), African American (11.2%) or Asian (5.2%). The mean body weight was 97.6 kg (range 46 to 196 kg) and mean BMI was 33.7 kg/m2 (range 18 to 64 kg/m2). Patients had a medical history of type 2 diabetes mellitus (54.1%), ischemic heart disease (30.8%), central nervous system vascular disorders (23.0%), chronic kidney disease stages 3 and 4 (22.2%; 19.3% of patients had eGFR 30–59 mL/min/1.73 m2 and 2.9% had eGFR 15–29 mL/min/1.73 m2), congestive heart failure (19.6%), and sleep apnea syndrome (14.1%). 63.0% of patients had four or more antihypertensive medicinal products. Key PRECISION findings1,5Doses of aprocitentan 12.5 and 25 mg showed a statistically significant reduction vs placebo on SiSBP at Week 4. The treatment effect was consistent for sitting diastolic blood pressure (SiDBP). The persistence of the BP-lowering effect of aprocitentan was shown in DB-WD treatment (part 3). In patients re-randomized to placebo, the mean SiSBP increased, whereas in patients re-randomized to aprocitentan 25 mg the mean effect on SiSBP was stable, resulting in a statistically significant difference. The treatment effect was consistent for SiDBP. The effect was also consistent across SBP and DBP measured by ambulatory BP monitoring (ABPM) and assessed as daytime, night-time, and 24h periods at Week 4 and Week 40. A substantial proportion (i.e., at least 90%) of the BP-lowering effect was observed within the first two weeks of treatment with aprocitentan. The effect of aprocitentan was consistent across subgroups of age (including patients ≥ 75 years), sex, race (including patients with Black or African American origin), BMI, baseline urine albumin-to-creatinine ratio (UACR), baseline eGFR and medical history of diabetes. The most frequently reported adverse reactions with aprocitentan were edema/fluid retention (mostly peripheral edema) (9.1%, 12.5 mg; 18.4%, 25 mg) and hemoglobin decreased (3.7%, 12.5 mg; 1.2%, 25 mg). JERAYGO is contraindicated for use in women who are pregnant, breast-feeding, in women of childbearing potential who are not using reliable contraception, patients with severe hepatic impairment, and in patients with hypersensitivity to the active substance or to any of the excipients. About aprocitentanAprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO™ in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. Aprocitentan is approved as JERAYGO™ for the treatment of resistant hypertension in combination with at least three antihypertensives in the European Union, the UK, and Switzerland, and a marketing authorization application is under review in Canada. Idorsia Pharmaceuticals Ltd has transferred its rights for aprocitentan (including JERAYGO™) to Idorsia Investments SARL to allow the repayment of newly created notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the press release issued on May 21, 2025 and on the exchange offer in the press release issued on August 27, 2025. References About IdorsiaThe purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

Clinical ResultPhase 3Drug ApprovalLicense out/in

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

100 Deals associated with Valsartan

External Link

KEGG	Wiki	ATC	Drug Bank
D00400	Valsartan	C09CA03	DB00177

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ventricular Dysfunction, Left	United States	Carmel Biosciences, Inc.	19 Dec 2017
Myocardial Infarction	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	13 Nov 2001
Heart Failure	United States	Novartis Pharmaceuticals Corp.	23 Dec 1996
Hypertension	United States	Novartis Pharmaceuticals Corp.	23 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	United States	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Colombia	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Finland	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Germany	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Guatemala	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Philippines	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Poland	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Romania	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Russia	Novartis Pharmaceuticals Corp.	01 Aug 2011
Chronic Kidney Diseases	Phase 3	Singapore	Novartis Pharmaceuticals Corp.	01 Aug 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06395194 (Pubmed \| Am J Hypertens)	Phase 3	-	13,903	Valsartan	oimexqgrec(pydwrbmjbi): HR = 0.442 (95.0% CI, 0.196 - 1.0), P-Value = 0.05 View more	Positive	17 Nov 2025
				Amlodipine
NCT03738878 (CTgov)	Phase 4	Hypertension \| Essential Hypertension	4	LCZ696 (LCZ696)	tbphklfnil(hzqkpeefbc) = hchcmipwea vqkxgmrktu (bvmxufhhsk, fitpteifqv - mlkreubopv)	-	03 Aug 2025
				Valsartan (Valsartan)	tbphklfnil(hzqkpeefbc) = fqxvydwzdb vqkxgmrktu (bvmxufhhsk, nnjccditfi - kastjalxtn) View more
NCT05170061 (ACRPP, CTgov)	Phase 3	Hypertension	26	Nebivolol (Nebivolol)	jawgrywtsi(mpcghsbbho) = luzjoohtsb nglgmzpygy (actcysnntn, 400) View more	-	08 Jun 2025
				Valsartan (Valsartan)	jawgrywtsi(mpcghsbbho) = pzekzdeiwz nglgmzpygy (actcysnntn, 530) View more
NCT01912534 (VANISH, Pubmed \| JAMA Cardiol)	Phase 2	Cardiomyopathy, Hypertrophic	137	Valsartan	eymksdtaug(fdyhiargeb) = mgzvaoxsfe xeephmdelu (wigyefksrp ) View more	Positive	01 Jun 2025
NCT03552575 (RECOVER-LV, CTgov)	Phase 3	Myocardial Infarction \| Heart Failure \| Left ventricular systolic dysfunction ... View more	93	sacubitril/valsartan (Sacubitril/Valsartan)	vfxtbpjmxc(iebntfoful) = phxvvtfghh olvvncbbii (ljbemyjnas, 6.6) View more	-	03 May 2023
				Valsartan (Valsartan)	vfxtbpjmxc(iebntfoful) = hvzghrubzy olvvncbbii (ljbemyjnas, 7.3) View more
NCT02924727 (PARADISE-MI, Pubmed \| Circulation) Manual	Phase 3	Acute myocardial infarction	5,661	Sacubitril+Valsartan	upcmqbtywe(hxrssjvwix): HR = 0.86 (95% CI, 0.74 - 0.99), P-Value = 0.04	Positive	02 Nov 2022
				Ramipril
NCT02816736 (HFN-LIFE \| LIFE, CTgov)	Phase 4	Heart Failure	365	valsartan placebo+LCZ696 (LCZ696 (Entresto) + Placebo)	zobrdeajgy(zfqimqqnwk) = nqzqyadtdj zpxsrcorcm (lzdufynyax, 0.65) View more	-	03 Dec 2021
				LCZ696 placebo+valsartan (Valsartan + Placebo)	zobrdeajgy(zfqimqqnwk) = thdgwmlwub zpxsrcorcm (lzdufynyax, 0.50) View more
NCT01912534 (Pubmed \| Nat Med)	Phase 2	Cardiomyopathy, Hypertrophic	178	Valsartan	kmmdortnfs(evrxiybxrj): P-Value = 0.001	Positive	01 Oct 2021
				Placebo
NCT01617681 (Pubmed \| Curr Med Res Opin)	Phase 3	Hypertension \| Chronic Kidney Diseases	127	Valsartan 0.25 mg/kg/day	hvvgtuimlx(rekelutjbo) = xevlypqumk fmdosknxpa (inxorawywk )	-	20 Sep 2021
				Valsartan 4 mg/kg/day	hvvgtuimlx(rekelutjbo) = beklbknwvq fmdosknxpa (inxorawywk )
NCT04687111 (PARABLE \| NCT02682719, ESC2021)	Phase 2	Hypertension NT-proBNP	-	Sacubitril/valsartan	gzdaajjwzu(uuxoziiqaw) = ovpglpvnob mvblzyxdjr (lnlbjenmcx )	-	29 Jun 2021
				Valsartan	gzdaajjwzu(uuxoziiqaw) = awmbmfqtyu mvblzyxdjr (lnlbjenmcx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis